The unmet need for COVID-19 treatment in immunocompromised patients

BMC Infectious Diseases

Correspondence

Nicastri Emanuele¹  D’Abramo Alessandra¹  Vita Serena¹ 

[1] National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Via Portuense 292, 00149, Rome, Italy;

关键词: Immunocompromised patients;    Severe and/or prolonged COVID-19;    Passive immunotherapy;    Antiviral therapy;    Combined therapy;   

DOI  :  10.1186/s12879-022-07918-x

 received in 2022-10-31, accepted in 2022-12-03,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundImmunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19.Main textThe recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants.ConclusionA tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed.

【 授权许可】

CC BY   
© The Author(s) 2022